Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Impact of an Information Sheet Given to Parents After an Initial Consultation for a Simple Febrile Seizure at Strasbourg University Hospital

NCT07335640 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-06-11
Last updated
2026-01-13

Condition(s) studied

Febrile Crisis

Study summary

Simple febrile seizures (SFS) are a very common phenomenon (2-5% of children), mostly without serious consequences for the child or their development, but extremely anxiety-provoking for parents, who develop a "fear of fever" for fear of a recurrence, and request numerous additional tests, not justified according to current guidelines, after a first episode of SFS.

Educating parents about these fever-related crises and fever management, and standardizing the information provided through an explanatory sheet implemented at the SAUP in July 2023, would help reduce consultations for recurrent simple febrile crises, as well as early consultations for isolated fever (reflecting parental anxiety caused by these crises).

Eligibility

Sex
ALL
Min age
9 Months
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * Child aged between 9 months and 5 years at the time of consultation at the SAUP (emergency pediatric unit) * First visit to the SAUP for a simple febrile seizure * Meeting the clinical criteria for FCS: * Generalized seizure lasting less than 15 minutes * No post-critical deficit * No recurrence of seizures within 24 hours * No personal history of neurological disorders * Occurrence between January 1, 2022, and May 1, 2025 * First or second episode of FSFS at the time of consultation * Presence of one of the two parents during the consultation at the SAUP Exclusion Criteria: * Patient already seen at the SAUP for FCS * Child who has already had more than two simple febrile seizures at the time of their visit to the emergency department. * Child who does not meet the criteria for simple febrile seizures: * aged less than 9 months or more than 5 years at the time of diagnosis. * Non-febrile seizure * Focal seizure * Seizure duration \>15 min * Presence of post-critical deficit * Multiple seizures within 24 hours * Personal neurological history. * Seizure occurring outside the period of interest (January 1, 2022 to May 1, 2025) * Absence of parents during the SAUP consultation

Primary outcome measure(s)

  • Number of consultations at the Pediatric Emergency Department for recurrent simple febrile crises. — Up to 4 years
    Number of consultations at the Pediatric Emergency Department (SAUP) for recurrent simple febrile crises.

Trial sites (1)

FacilityCityRegionStatus
Service de pédiatrie 1 - CHU de Strasbourg - France Strasbourg France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07335640 on ClinicalTrials.gov ↗ ← All trials in France